The AmpliSeq for Illumina Immune Response Panel is a targeted resequencing research assay for quantitating expression of cancer biomarkers in 395 genes involved in tumor–immune system interactions. Key features include:
Relevant Gene Content
Targeted expression of 395 cancer biomarkers indicative of immunotherapy response
Fast, Streamlined Workflow
Prepare sequencing-ready libraries in a single day from as little as 1 ng of high quality RNA or 10 ng of formalin-fixed, paraffin-embedded (FFPE) RNA input samples
Detect expression of genes involved in tumor-immune interactions
The Immune Response Panel is part of an integrated RNA-to-annotated variant solution that includes AmpliSeq for Illumina polymerase chain reaction (PCR)-based library preparation, Illumina sequencing by synthesis (SBS) next-generation sequencing (NGS) technology, and automated analysis.
This panel detects biomarkers associated with different leukocyte subsets, antigen presentation, checkpoint pathways, and tumor progression. The ready-to-use panel saves you the time and effort of identifying targets, designing primers, and optimizing panels.